CN104587536A - Biodegradable polymer coating drug-loaded magnesium alloy eluting stent - Google Patents
Biodegradable polymer coating drug-loaded magnesium alloy eluting stent Download PDFInfo
- Publication number
- CN104587536A CN104587536A CN201410840287.9A CN201410840287A CN104587536A CN 104587536 A CN104587536 A CN 104587536A CN 201410840287 A CN201410840287 A CN 201410840287A CN 104587536 A CN104587536 A CN 104587536A
- Authority
- CN
- China
- Prior art keywords
- magnesium alloy
- coating
- polymer
- firebirdtm
- biodegradable polymer
- Prior art date
- Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
- Pending
Links
Landscapes
- Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
- Medicinal Preparation (AREA)
Abstract
The invention provides a biodegradable polymer coating drug-loaded magnesium alloy eluting stent. The eluting stent comprises a magnesium alloy bare stent with a supporting effect, a hyaluronic acid coating which coats the surface of the magnesium alloy bare stent, a degradable coating which coats the surface of the hyaluronic acid coating, and a medicinal coating adhered to the surface of the degradable coating, wherein the degradable coating is prepared from acylated chitosan, degradable high-molecular polymer and bioactive substances in a physical blending mode. According to the magnesium alloy eluting stent, the local microenvironment around the magnesium alloy stent is controlled to be neutral or weak alkaline by acylated chitosan, so that the magnesium alloy stent is protected, and the degrading speed of the magnesium alloy stent is controlled; an excellent binding force is formed with the magnesium alloy bare stent and the medicinal coating by means of the degradable high-molecular polymer, and the medicine releasing speed is controlled, thrombus is prevented by means of the bioactive substances, the endothelialization process and vascular wall healing can be accelerated, and hyperblastosis is resisted by means of anti-restenosis medicines.
Description
Technical field
The present invention relates to bracket for eluting medicament technical field, particularly, relate to a kind of biodegradable polymer coating medicine carrying magnesium alloy FirebirdTM.
Background technology
Bracket for eluting medicament (DES) is the important method of current cardiovascular disease interventional therapy.DES carries medicine by the degradable polymer coating being coated in metal support surface, and medicine is slow releasing from party thing, thus suppresses local smoothing method myocyte increment or antithrombotic, in-stent restenosis incidence rate is reduced within 10%.
Degradable polymer conventional is at present polylactic acid (PLA) etc.; polylactic acid easily causes in acid matrix microenvironment in degradation process; sour environment can accelerate the degradation speed of magnesium alloy bracket; therefore; around conservative control magnesium alloy bracket, local microenvironment is neutral or alkalescence; to protect magnesium alloy bracket, control its degradation speed, there is great researching value.
Summary of the invention
The object of the present invention is to provide a kind of biodegradable polymer coating medicine carrying magnesium alloy FirebirdTM; controlling local microenvironment around magnesium alloy bracket by acylation chitosan is neutral or alkalescence; to protect magnesium alloy bracket; control its degradation speed; good adhesion is formed by degradable polymer polymer and magnesium alloy bare bracket and medication coat; and control the rate of release of medicine; by the anti-tampon of bioactive substance; accelerate endothelialization process and blood vessel wall healing, by the anti-hamartoplasia of medicine.
Technical scheme of the present invention is as follows: a kind of biodegradable polymer coating medicine carrying magnesium alloy FirebirdTM; Comprise the magnesium alloy bare bracket with supporting role; Be coated on the hyaluronic acid coatings on magnesium alloy bare bracket surface; Be coated on the degradability coating on hyaluronic acid coatings surface; And adhere to the medication coat of described degradability coating surface.
Described degradability coating is that acylation chitosan and degradable polymer polymer and bioactive substance obtain in the mode of physical blending thing.Concrete mode is: three mixed with the sodium chloride particle of constant weight with certain mass ratio, drops in vacuum tightness system, strong stirring 30min at 80-120 DEG C, drops in distilled water and leach sodium chloride, vacuum drying.
Described magnesium alloy bare bracket is magnesium selenium manganese alloy, magnesium selenium manganese calcium alloy or magnesium calcium alloy.
Chitosan is a kind of alkaline polysaccharide, has nontoxic, biodegradable, and looks capacitive well waits good characteristic.There is acylation reaction and obtain acylation chitosan in chitosan and lauroyl chloride, in this acylation reaction, the mol ratio of lauroyl chloride and chitosan unit is 3-7:1, and the molecular weight of gained acylation chitosan is 200000-1000000 in acid medium.The introducing of carboxyl groups, makes the hydrophobic interaction between chitosan side chain strengthen, improves the stability of chitosan derivatives.Simultaneously; in alkalescence during acylation chitosan degraded, neutralize the acidity of degradable polymer polymer degradation products, thus form a comparatively stable neutral environment at magnesium alloy bare bracket surf zone; delay the degradation time of magnesium alloy, reach the object of progressively degrading.In addition; the dispose procedure of medicine being coated in degradability bioactive substance surface is relevant with the length of the acylation degree of acylation chitosan and acyl group carbon lotus, shows good medicine-releasing performance, Drug controlled release speed; acute after can reducing stenter to implant, subacute stent thrombosis odds.
Described degradable polymer polymer should have good biocompatibility, has and will control the rate of release of medicine as the carrier of anti-restenosis drug, simultaneously also must with magnesium alloy bare bracket, hyaluronic acid coatings and medication coat form good adhesion.Described degradable polymer polymer is polylactic acid, Poly(D,L-lactide-co-glycolide, polyglycolic acid, poly phosphate and copolymer thereof, the one in mixture or derivant.Wherein, described polylactic acid (PLA) preferred number average molecular weight is (Mn) 70000-150000, Poly(D,L-lactide-co-glycolide preferred number average molecular weight is (Mn) 10000-150000, polyglycolic acid preferred number average molecular weight is (Mn) 3000-5000, and poly phosphate preferred number average molecular weight is (Mn) 130000-170000.
Described bioactive substance can prevent acute thrombus, subacute stent thrombosis and advanced thrombus, and can promote that endotheliocyte adheres to and growth at material surface, accelerate rack surface and blood vessel wall endothelialization process, acceleration injured vessel wall heals, be selected from hirudin, factor Xa inhibitor, factor VIIa inhibitors, heparin, low molecular sodium heparin, the mixture of one or several in the PROTEIN C of low molecular heparin calcium, activation, Antithrombin III, heparin co factor II, Coumarins, defibrase.
Described degradability coating layer thickness is 1-100um; In described degradability coating, described bioactive ingredients content is the 1-70% of acylation chitosan and degradable polymer polymer weight, preferred 1-50%; The mass ratio of described acylation chitosan and described degradable polymer polymer is 10:1-3.
Described medication coat is that described degradable polymer polymer and described anti-restenosis drugs obtain in the mode of physical blending.
Described anti-restenosis drugs has good anti-hamartoplasia effect, is paclitaxel, rapamycin, emodin, dexamethasone, dactinomycin, heparin, hirudin, beta estradiol etc.
The thickness of described medication coat is 1-100um, and in described medication coat, described anti-restenosis drugs content is the 1-60% of described degradable polymer polymer weight, preferred 10-40%.
Described hyaluronic acid coatings thickness is 1-100um.
Described preparation method is adopt conventional spraying coating process, and first hyaluronic acid is sprayed at magnesium alloy bare bracket surface and forms described hyaluronic acid coatings.Then, described acylation chitosan and degradable polymer polymer and bioactive substance are obtained blend by physical mixed.Described blend is placed in nebulizer be atomized, is then sprayed at hyaluronic acid coatings surface, obtains biodegradable coating.Then described degradable polymer polymer and the mixing of described anti-restenosis drugs are placed in nebulizer and are atomized, be then sprayed at biodegradable coating surface, obtain medication coat.
The magnesium alloy medicine FirebirdTM prepared by said method, biodegradable coating and medication coat have enough strong adhesion, magnesium alloy bare bracket surface can be sticked to uniformly and stably, medication coat plays antiproliferative effect, thus prevent the generation of restenosis, when after medication coat degraded, described biodegradable coating is exposed in blood, the generation of anti-tampon, after biodegradable coating degraded, hyaluronic acid coatings delays the degraded of described magnesium alloy bare bracket further, thus states the useful life of magnesium alloy bare bracket described in having extended described.
Detailed description of the invention
Embodiment 1:
A kind of biodegradable polymer coating medicine carrying magnesium alloy FirebirdTM; Be coated on the hyaluronic acid coatings on magnesium alloy bare bracket surface; Be coated on the degradability coating on hyaluronic acid coatings surface; And adhere to the medication coat of described degradability coating surface; Described degradability coating is that acylation chitosan and degradable polymer polymer and bioactive substance obtain in the mode of physical blending thing.
Described magnesium alloy bare bracket is magnesium calcium alloy.
Described hyaluronic acid coatings thickness is 10um.The acid of nanometer transparent matter is surperficial in described magnesium alloy bare bracket by spray coating.
Described degradability coating is that acylation chitosan and degradable polymer polymer and bioactive substance obtain in the mode of physical blending thing.Wherein, acylation chitosan is that lauroyl chloride in acid medium, acylation reaction occurs with mol ratio 5:1 in chitosan unit, prepares acylation chitosan, and molecular weight is 200000.Described degradable polymer polymer is polylactic acid, and number-average molecular weight is (Mn) 70000-150000.Described bioactive substance is Antithrombin III.By above-mentioned three kinds of materials by after physical blending, be placed in nebulizer and be atomized, be then sprayed at hyaluronic acid coatings surface, obtain biodegradable coating.Described biodegradable coating thickness is 50um, and wherein, described bioactive ingredients content is 50% of acylation chitosan and degradable polymer polymer weight.The mass ratio of described acylation chitosan and described degradable polymer polymer is 10:2.
Described medication coat is that described degradable polymer polymer and anti-restenosis drugs obtain in the mode of physical blending.Described degradable polymer polymer is polylactic acid, and number-average molecular weight is (Mn) 70000-150000.Described medicine is paclitaxel.The thickness of described medication coat is 30um, and described medicament contg is 30% of described degradable polymer polymer weight.Described degradable polymer polymer and the mixing of described anti-restenosis drugs are placed in nebulizer and are atomized, be then sprayed at biodegradable coating, obtain medication coat.
Embodiment 2
A kind of biodegradable polymer coating medicine carrying magnesium alloy FirebirdTM; Be coated on the hyaluronic acid coatings on magnesium alloy bare bracket surface; Be coated on the degradability coating on hyaluronic acid coatings surface; And adhere to the medication coat of described degradability coating surface; Described degradability coating is that acylation chitosan and degradable polymer polymer and bioactive substance obtain in the mode of physical blending thing.
Described magnesium alloy bare bracket is magnesium calcium alloy.
Described hyaluronic acid coatings thickness is 0.05um.The acid of nanometer transparent matter is surperficial in described magnesium alloy bare bracket by spray coating.
Described degradability coating is that acylation chitosan and degradable polymer polymer and bioactive substance obtain in the mode of physical blending thing.Wherein, acylation chitosan is that lauroyl chloride in acid medium, acylation reaction occurs with mol ratio 5:1 in chitosan unit, prepares acylation chitosan, and molecular weight is 500000.Described degradable polymer polymer is Poly(D,L-lactide-co-glycolide, and number-average molecular weight is (Mn) 10000-150000.Described bioactive substance is heparin.By above-mentioned three kinds of materials by after physical blending, be placed in nebulizer and be atomized, be then sprayed at hyaluronic acid coatings surface, obtain biodegradable coating.Described biodegradable coating thickness is 100um, and wherein, described bioactive ingredients content is 70% of acylation chitosan and degradable polymer polymer weight.The mass ratio of described acylation chitosan and described degradable polymer polymer is 10:3.
Described medication coat is described degradable polymer polymer, and silver ion and anti-restenosis drugs obtain in the mode of physical blending.Described degradable polymer polymer is Poly(D,L-lactide-co-glycolide, and number-average molecular weight is (Mn) 3000-5000.Described medicine is heparin.The thickness of described medication coat is 70um, and described medicament contg is 40% of described degradable polymer polymer weight.Described silver ion content is 5% of described degradable polymer polymer weight.By described degradable polymer polymer, described silver ion and described medicament mixed are placed in nebulizer and are atomized, and are then sprayed at biodegradable coating, obtain medication coat.
Embodiment 3
A kind of biodegradable polymer coating medicine carrying magnesium alloy FirebirdTM; Be coated on the hyaluronic acid coatings on magnesium alloy bare bracket surface; Be coated on the degradability coating on hyaluronic acid coatings surface; And adhere to the medication coat of described degradability coating surface; Described degradability coating is that acylation chitosan and degradable polymer polymer and bioactive substance obtain in the mode of physical blending thing.
Described magnesium alloy bare bracket is magnesium selenium manganese alloy.
Described hyaluronic acid coatings is thickness is 50um.The acid of nanometer transparent matter is surperficial in described magnesium alloy bare bracket by spray coating.
Described degradability coating is that acylation chitosan and degradable polymer polymer and bioactive substance obtain in the mode of physical blending thing.Wherein, acylation chitosan is that lauroyl chloride in acid medium, acylation reaction occurs with mol ratio 5:1 in chitosan unit, prepares acylation chitosan, and molecular weight is 700000.Described degradable polymer polymer is poly phosphate, and number-average molecular weight is (Mn) 130000-170000.Described bioactive substance is factor Xa inhibitor.By above-mentioned three kinds of materials by after physical blending, be placed in nebulizer and be atomized, be then sprayed at hyaluronic acid coatings surface, obtain biodegradable coating.Described biodegradable coating thickness is 1um, and wherein, described bioactive ingredients content is 1% of acylation chitosan and degradable polymer polymer weight.The mass ratio of described acylation chitosan and described degradable polymer polymer is 10:1.
Described medication coat is described degradable polymer polymer, and silver ion and anti-restenosis drugs obtain in the mode of physical blending.Described degradable polymer polymer is poly phosphate, and number-average molecular weight is (Mn) 130000-170000.Described medicine is rapamycin.The thickness of described medication coat is 100um, and described medicament contg is 60% of described degradable polymer polymer weight.Described silver ion content is 3% of described degradable polymer polymer weight.By described degradable polymer polymer, described silver ion and the mixing of described anti-restenosis drugs are placed in nebulizer and are atomized, and are then sprayed at biodegradable coating, obtain medication coat.
Embodiment 4
A kind of biodegradable polymer coating medicine carrying magnesium alloy FirebirdTM; Be coated on the hyaluronic acid coatings on magnesium alloy bare bracket surface; Be coated on the degradability coating on hyaluronic acid coatings surface; And adhere to the medication coat of described degradability coating surface; Described degradability coating is that acylation chitosan and degradable polymer polymer and bioactive substance obtain in the mode of physical blending thing.
Described magnesium alloy bare bracket is magnesium selenium manganese calcium alloy.
Described hyaluronic acid coatings thickness is 100um.The acid of nanometer transparent matter is surperficial in described magnesium alloy bare bracket by spray coating.
Described degradability coating is that acylation chitosan and degradable polymer polymer and bioactive substance obtain in the mode of physical blending thing.Wherein, acylation chitosan is that lauroyl chloride in acid medium, acylation reaction occurs with mol ratio 5:1 in chitosan unit, prepares acylation chitosan, and molecular weight is 1000000.Described degradable polymer polymer is polyglycolic acid, and number-average molecular weight is (Mn) 3000-5000.Described bioactive substance is hirudin.By above-mentioned three kinds of materials by after physical blending, be placed in nebulizer and be atomized, be then sprayed at hyaluronic acid coatings surface, obtain biodegradable coating.Described biodegradable coating thickness is 100um, and wherein, described bioactive ingredients content is 20% of acylation chitosan and degradable polymer polymer weight.The mass ratio of described acylation chitosan and described degradable polymer polymer is 10:2.
Described medication coat is described degradable polymer polymer, and silver ion and anti-restenosis drugs obtain in the mode of physical blending.Described degradable polymer polymer is polyglycolic acid, and number-average molecular weight is (Mn) 3000-5000.Described medicine is beta estradiol.The thickness of described medication coat is 1um, and described medicament contg is 10% of described degradable polymer polymer weight.Described silver ion content is 1% of described degradable polymer polymer weight.By described degradable polymer polymer, described silver ion and the mixing of described anti-restenosis drugs are placed in nebulizer and are atomized, and are then sprayed at biodegradable coating, obtain medication coat.
Above content is in conjunction with concrete preferred implementation further description made for the present invention, can not assert that specific embodiment of the invention is confined to these explanations.For general technical staff of the technical field of the invention, without departing from the inventive concept of the premise, its framework form can be flexible and changeable, can subseries product.Just make some simple deduction or replace, all should be considered as belonging to the scope of patent protection that the present invention is determined by submitted to claims.
Claims (10)
1. a biodegradable polymer coating medicine carrying magnesium alloy FirebirdTM, is characterized in that, comprises the magnesium alloy bare bracket with supporting role; Be coated on the hyaluronic acid coatings on magnesium alloy bare bracket surface; Be coated on the degradability coating on hyaluronic acid coatings surface; And adhere to the medication coat of described degradability coating surface; Described degradability coating is that acylation chitosan and degradable polymer polymer and bioactive substance obtain in the mode of physical blending thing.
2. biodegradable polymer coating medicine carrying magnesium alloy FirebirdTM as claimed in claim 1; it is characterized in that; described acylation chitosan be chitosan and lauroyl chloride occur in acid medium acylation reaction obtain; in this acylation reaction, the mol ratio of lauroyl chloride and chitosan unit is 3-7:1.
3. biodegradable polymer coating medicine carrying magnesium alloy FirebirdTM as claimed in claim 1 or 2, it is characterized in that, described degradable polymer polymer is polylactic acid, Poly(D,L-lactide-co-glycolide, polyglycolic acid, poly phosphate and copolymer thereof, the one in mixture or derivant.
4. biodegradable polymer coating medicine carrying magnesium alloy FirebirdTM as claimed in claim 3, it is characterized in that, described polylactic acid (PLA) number-average molecular weight is (Mn) 70000-150000, Poly(D,L-lactide-co-glycolide number-average molecular weight is (Mn) 10000-150000, polyglycolic acid number-average molecular weight is (Mn) 3000-5000, and poly phosphate number-average molecular weight is (Mn) 130000-170000.
5. as claim 1, biodegradable polymer coating medicine carrying magnesium alloy FirebirdTM described in 2 or 4, it is characterized in that, described bioactive substance is selected from hirudin, factor Xa inhibitor, factor VIIa inhibitors, heparin, low molecular sodium heparin, the mixture of one or several in the PROTEIN C of low molecular heparin calcium, activation, antithrombase I II, heparin co factor II, Coumarins, defibrase.
6. the biodegradable polymer coating medicine carrying magnesium alloy FirebirdTM as described in claim 1,2 or 4, it is characterized in that, described degradability coating layer thickness is 1-100um.
7. as claim 1; biodegradable polymer coating medicine carrying magnesium alloy FirebirdTM described in 2 or 4; it is characterized in that; in described degradability coating; described bioactive ingredients content is the 1-70% of acylation chitosan and degradable polymer polymer weight, and the mass ratio of described acylation chitosan and described degradable polymer polymer is 10:1-3.
8. biodegradable polymer coating medicine carrying magnesium alloy FirebirdTM as claimed in claim 1, it is characterized in that, described medication coat comprises described degradable polymer polymer and anti-restenosis drugs.
9. biodegradable polymer coating medicine carrying magnesium alloy FirebirdTM as claimed in claim 8, it is characterized in that, described anti-narrow medicine is again paclitaxel, rapamycin, emodin, dexamethasone, dactinomycin, heparin, hirudin, the mixture of one or several in beta estradiol.
10. biodegradable polymer coating medicine carrying magnesium alloy FirebirdTM as claimed in claim 1, it is characterized in that, the thickness of described medication coat is 1-100um, and in described medication coat, described anti-restenosis drugs content is the 1-60% of described degradable polymer polymer weight.
Priority Applications (1)
| Application Number | Priority Date | Filing Date | Title |
|---|---|---|---|
| CN201410840287.9A CN104587536A (en) | 2014-12-30 | 2014-12-30 | Biodegradable polymer coating drug-loaded magnesium alloy eluting stent |
Applications Claiming Priority (1)
| Application Number | Priority Date | Filing Date | Title |
|---|---|---|---|
| CN201410840287.9A CN104587536A (en) | 2014-12-30 | 2014-12-30 | Biodegradable polymer coating drug-loaded magnesium alloy eluting stent |
Publications (1)
| Publication Number | Publication Date |
|---|---|
| CN104587536A true CN104587536A (en) | 2015-05-06 |
Family
ID=53113802
Family Applications (1)
| Application Number | Title | Priority Date | Filing Date |
|---|---|---|---|
| CN201410840287.9A Pending CN104587536A (en) | 2014-12-30 | 2014-12-30 | Biodegradable polymer coating drug-loaded magnesium alloy eluting stent |
Country Status (1)
| Country | Link |
|---|---|
| CN (1) | CN104587536A (en) |
Citations (3)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| CN101869723A (en) * | 2009-04-27 | 2010-10-27 | 赵菁 | Composite medicament stent for inhibiting cardiovascular restenosis and preparation method |
| CN102488932A (en) * | 2011-12-22 | 2012-06-13 | 哈尔滨工程大学 | Magnesium alloy support coated with acylated chitosan and polyester blend medicine coating |
| CN102772831A (en) * | 2012-08-20 | 2012-11-14 | 道淼科技(北京)有限公司 | Degradable drug loading stent |
-
2014
- 2014-12-30 CN CN201410840287.9A patent/CN104587536A/en active Pending
Patent Citations (3)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| CN101869723A (en) * | 2009-04-27 | 2010-10-27 | 赵菁 | Composite medicament stent for inhibiting cardiovascular restenosis and preparation method |
| CN102488932A (en) * | 2011-12-22 | 2012-06-13 | 哈尔滨工程大学 | Magnesium alloy support coated with acylated chitosan and polyester blend medicine coating |
| CN102772831A (en) * | 2012-08-20 | 2012-11-14 | 道淼科技(北京)有限公司 | Degradable drug loading stent |
Similar Documents
| Publication | Publication Date | Title |
|---|---|---|
| CN104587535A (en) | Biodegradable polymer coating drug-loaded magnesium alloy eluting stent | |
| Zhang et al. | Advances in coatings on magnesium alloys for cardiovascular stents–a review | |
| CN104189963B (en) | Reduction can the preparation method of surface coating of degradable magnesium alloy blood vessel rack degradation rate | |
| EP2212391B1 (en) | Polymer blends for drug delivery stent matrix with improved thermal stability | |
| Tesfamariam | Bioresorbable vascular scaffolds: Biodegradation, drug delivery and vascular remodeling | |
| CA2462723C (en) | Coated stents for preventing restenosis | |
| Wei et al. | Hemocompatibility and selective cell fate of polydopamine-assisted heparinized PEO/PLLA composite coating on biodegradable AZ31 alloy | |
| EP2442841B1 (en) | Implantable medical devices and coatings therefor comprising block copolymers of poly (ethylene glycol) and a poly (lactide-glycolide) | |
| CN101861175B (en) | Coating | |
| CN102166141B (en) | Process for preparing drug eluting stent | |
| Tang et al. | A surface-eroding poly (1, 3-trimethylene carbonate) coating for magnesium based cardiovascular stents with stable drug release and improved corrosion resistance | |
| MXPA04011112A (en) | Compounds and method for coating surfaces in a haemocompatible manner. | |
| US20130103139A1 (en) | Coating of endoprostheses with a coating consisting of a tight mesh of polymer fibers | |
| CN104491935A (en) | Drug-loading magnesium alloy eluting stent for biodegradable polymer coating | |
| JP2008289853A (en) | Coating agent for medical equipment which has anti-thrombus conjugate | |
| US7264822B2 (en) | Conjugated drug-polymer coated stent | |
| CN106730050A (en) | A kind of preparation method of the multifunctional drug eluting coatings for intravascular stent | |
| CN101703428B (en) | Intravascular scaffold provided with anti-restenosis coating layer and preparation method thereof | |
| CN101711710B (en) | Medicament eluting stent and preparation method thereof | |
| CN104524647A (en) | Biodegradable polymer coating drug-loaded magnesium alloy-eluting stent | |
| CN104587538A (en) | Magnesium alloy eluting stent with biodegradable polymer coatings carrying drugs | |
| Rebelo et al. | Poly lactic acid fibre based biodegradable stents and their functionalization techniques | |
| CN107913119A (en) | A kind of interventional medical device and preparation method thereof | |
| CN104523660A (en) | Biodegradable polymer coating drug-loaded magnesium alloy-eluting stent | |
| Chen et al. | Biomimetic apatite formed on cobalt-chromium alloy: A polymer-free carrier for drug eluting stent |
Legal Events
| Date | Code | Title | Description |
|---|---|---|---|
| C06 | Publication | ||
| PB01 | Publication | ||
| C10 | Entry into substantive examination | ||
| SE01 | Entry into force of request for substantive examination | ||
| CB02 | Change of applicant information |
Address after: 523000 Guangdong province Dongguan Nancheng District new historical garden Fu Zhu Yuan building 1002 room 10 Applicant after: Ma Yanrong Address before: No. 14, Lane 12, hay Road, Dongcheng District, Dongguan, Guangdong Applicant before: Ma Yanrong |
|
| COR | Change of bibliographic data | ||
| WD01 | Invention patent application deemed withdrawn after publication |
Application publication date: 20150506 |
|
| WD01 | Invention patent application deemed withdrawn after publication |